Patents by Inventor Ugur Sahin

Ugur Sahin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210283177
    Abstract: The present invention relates to cells which are engineered so as to increase the cellular level of cellular FLICE [Fas-associated death domain (FADD)-like IL-1?-converting enzyme]—inhibitory protein (CFLAR). The engineered cells have the ability to induce tolerance. Enhanced tolerogenicity is useful for prolonging survival of a foreign transplant and for treatment of autoimmune diseases.
    Type: Application
    Filed: September 17, 2018
    Publication date: September 16, 2021
    Inventors: Ugur Sahin, Vincenzo Bronte, Stefano Ugel, Alessandra Fiore
  • Publication number: 20210277133
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 9, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • Publication number: 20210269541
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 2, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • Publication number: 20210253725
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Patent number: 11091557
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 17, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Publication number: 20210246191
    Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.
    Type: Application
    Filed: June 6, 2019
    Publication date: August 12, 2021
    Inventors: Ugur Sahin, Bonny Gaby Lui, Nadja Salomon, Joycelyn Wüstehube-Lausch, Matin Daneschdar, Hans-Ulrich Schmoldt, Markus Fiedler
  • Patent number: 11084882
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 10, 2021
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Patent number: 11045418
    Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 29, 2021
    Assignees: BioNTech RNA Pharmaceuticals GmbH, Tron-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer
  • Patent number: 11046745
    Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3?). These molecules compete with CD3? for binding to a CD3? binding domain. e.g. a CD3? binding domain of an antibody, and are capable of detecting antibodies against CD3?. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3? antibody purification and the detection of anti-CD3? antibodies in biological samples.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: June 29, 2021
    Assignees: BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, JPT Peptide Technologies GmbH
    Inventors: Ugur Sahin, Laura Marie Kring, Markus Fiedler, Matin Daneschdar, Hans-Ulrich Schmoldt, Ulf Reimer, Karsten Schnatbaum
  • Publication number: 20210179730
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: December 30, 2020
    Publication date: June 17, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Publication number: 20210163616
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • Publication number: 20210164034
    Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
    Type: Application
    Filed: July 2, 2020
    Publication date: June 3, 2021
    Inventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Lower, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
  • Publication number: 20210145700
    Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
    Type: Application
    Filed: October 23, 2020
    Publication date: May 20, 2021
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Koslowski, Stefan Fritz, Harald-Gerhard Geppert
  • Patent number: 11008550
    Abstract: The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: May 18, 2021
    Inventors: Ugur Sahin, Marco Poleganov, Tim Beissert
  • Publication number: 20210113606
    Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising co-administering to the subject RNA encoding peptides or proteins used for vaccination and RNA encoding IL-2 attached to a pharmacokinetic modifying group and/or RNA encoding IL-7 attached to a pharmacokinetic modifying group. The vaccine is particularly effective if an immune checkpoint inhibitor such as an anti-PD-L1 antibody is further administered. The present disclosure further relates to methods involving the target-specific delivery of a cytokine to a target organ or target tissue.
    Type: Application
    Filed: February 8, 2019
    Publication date: April 22, 2021
    Inventors: Ugur Sahin, Lena Kranz, Mathias Vormehr, Mustafa Diken, Sebastian Kreiter, Bodo Tillmann
  • Patent number: 10968280
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: April 6, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz
  • Publication number: 20210079113
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Application
    Filed: October 15, 2020
    Publication date: March 18, 2021
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
  • Patent number: 10946069
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 16, 2021
    Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Patent number: 10927181
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: February 23, 2021
    Assignees: BIONTECH SE, GENMAB A/S
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Patent number: 10927413
    Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: February 23, 2021
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNTVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSIT MAINZ GGMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus